The Asian Pacific Association for the Study of the Liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitis Guiqiang WangAtsushi TanakaShiv Kumar Sarin Guidelines Open access 04 May 2021 Pages: 223 - 257
Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines Harshad DevarbhaviGuruprasad Aithalon behalf of the Asia Pacific Association of Study of Liver Guidelines 27 February 2021 Pages: 258 - 282
Targeting the ileal bile salt transporter in the treatment of non-alcoholic fatty liver disease Peter L. M. Jansen Editorial Open access 01 February 2021 Pages: 283 - 286
Toward a new landscape for the mechanism of immunosuppression in hepatocellular carcinoma Chien-Wei SuHan-Chieh Lin Editorial 13 March 2021 Pages: 287 - 289
Chronic hepatitis B: the demise of the ‘inactive carrier’ phase Apostolos KoffasManoj KumarS. K. Sarin Review Article 27 February 2021 Pages: 290 - 300
Combining end-of-treatment HBsAg and baseline hepatitis B core-related antigen reduce HBV relapse rate after tenofovir cessation Yuan-Hung KuoJing-Houng WangChien-Hung Chen Original Article 04 March 2021 Pages: 301 - 309
A novel evidence of serial changes of bone mineral density in chronic hepatitis B patients treated with entecavir Pao-Yuan HuangSherry Yueh-Hsia ChiuTsung-Hui Hu Original Article 27 April 2021 Pages: 310 - 317
High-normal alanine aminotransferase is an indicator for liver histopathology in HBeAg-negative chronic hepatitis B Menghui DuanXiaoling ChiHui Zhuang Original Article 26 February 2021 Pages: 318 - 327
Neonatal hepatitis B vaccination protects mature adults from occult virus infection Ruijun WangChang LiuChunfeng Qu Original Article 22 March 2021 Pages: 328 - 337
Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan Chen-Hua LiuPo-Yueh ChenJia-Horng Kao Original Article 06 March 2021 Pages: 338 - 349
Gut-liver axis modulation of Panax notoginseng saponins in nonalcoholic fatty liver disease Yu XuNing WangYibin Feng Original Article Open access 03 March 2021 Pages: 350 - 365
The epidemiology of NAFLD and lean NAFLD in Japan: a meta-analysis with individual and forecasting analysis, 1995–2040 Takanori ItoMasatoshi IshigamiMindie H. Nguyen Original Article 12 February 2021 Pages: 366 - 379
Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD? Gabriel Tayguara Silveira GuerreiroLarisse LongoMário Reis Álvares-da-Silva Original Article 10 March 2021 Pages: 380 - 391
Elobixibat, an ileal bile acid transporter inhibitor, ameliorates non-alcoholic steatohepatitis in mice Ryo YamauchiHidetoshi TakedatsuFumihito Hirai Original Article 04 January 2021 Pages: 392 - 404
The metabolic profiles and body composition of lean metabolic associated fatty liver disease Yu-Ming ChengJia-Horng KaoChia-Chi Wang Original Article 04 February 2021 Pages: 405 - 412
Liver fibrosis scores and coronary atherosclerosis: novel findings in patients with stable coronary artery disease Jing-Lu JinHui-Wen ZhangJian-Jun Li Original Article 19 March 2021 Pages: 413 - 423
The longitudinal outcomes of applying non-selective beta-blockers in portal hypertension: real-world multicenter study Seong Hee KangMinjong LeeSoon Koo Baik Original Article 16 April 2021 Pages: 424 - 436
Paris II and Rotterdam criteria are the best predictors of outcomes in patients with primary biliary cholangitis in Japan Naruhiro KimuraMasaaki TakamuraShuji Terai Original Article 16 April 2021 Pages: 437 - 443
Dual targeting of PD-L1 and PD-L2 by PCED1B-AS1 via sponging hsa-miR-194-5p induces immunosuppression in hepatocellular carcinoma Fei FanKeji ChenBin Wu Original Article 21 November 2020 Pages: 444 - 458
Development and validation of an individualized prediction calculator of postoperative mortality within 6 months after surgical resection for hepatocellular carcinoma: an international multicenter study Lei LiangBing QuanTian Yang Original Article 03 February 2021 Pages: 459 - 471
Clinical manifestations and outcomes of patients with scirrhous hepatocellular carcinoma Shang-Chin HuangSih-Han LiaoJia-Horng Kao Original Article 05 February 2021 Pages: 472 - 481
Weight fluctuation and risk of hepatocellular carcinoma: a nationwide population-based 8-million-subject study Young ChangJeong-Ju YooSu Jong Yu Original Article 17 February 2021 Pages: 482 - 492
Liver injury predicts overall mortality in severe COVID-19: a prospective multicenter study in Brazil Fernanda Manhães PozzobonHugo PerazzoMaria Chiara Chindamo Original Article 03 February 2021 Pages: 493 - 501
Dynamic Optic Nerve Sheath Diameter (ONSD) guided management of raised intracranial pressure in pediatric acute liver failure Priti VijayBikrant Bihari LalSeema Alam Original Article 24 February 2021 Pages: 502 - 509
Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients Maaike BiewengaMonique K. van der KooijEllen Kapiteijn Original Article Open access 25 February 2021 Pages: 510 - 519
Thromboelastometry in patients with advanced chronic liver disease: a complex interplay Sanchit Sharma Letter to the Editor 29 January 2021 Pages: 520 - 521
Author’s reply to “Thromboelastometry in patients with advanced chronic liver disease: a complex interplay” Pierre RaevenMattias MandorferBenedikt Simbrunner Letter to the Editor 17 February 2021 Pages: 522 - 524
The prevalence of occult HBV infection in immunized children with HBs Ag positive parents: a hospital based analysis Srinith B. PatilManoj Kumar SahuGirish Kumar Pati Letter to the Editor 18 February 2021 Pages: 525 - 525
C1QTNF1-AS1 regulates the occurrence and development of hepatocellular carcinoma by regulating miR-221-3p/SOCS3 Jiong Lin Letter to the Editor 10 February 2021 Pages: 526 - 526
The main reasons for finite Nuc therapy in HBeAg-negative chronic hepatitis B patients Chien-Wei PengWen-Juei Jeng Letter to the Editor 27 April 2021 Pages: 527 - 528
Correction to: Targeting the ileal bile salt transporter in the treatment of non‑alcoholic fatty liver disease Peter L. M. Jansen Correction 22 April 2021 Pages: 529 - 529